Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PBP1510 in Advanced/Metastatic Pancreatic Cancer
NCT05141149Phase 2Active, not recruiting
- Sponsor
- Prestige Biopharma Limited
- Start
- Jun 2023
- Primary completion
- Jul 2026
- Modality
- scFv Fragments, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, open-label trial of ulenistamab in pancreatic cancer (PC) (10 cohorts), sponsored by Prestige Biopharma Limited. Primary endpoints: Safety and tolerability of PBP1510, Dose limiting toxicity at 28 days and 1 more. Started Jun 2023; status: active, not recruiting.
02
Drugs
ulenistamab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05141149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05141149.